The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
Takeda Pharmaceutical said on November 7 that its dengue vaccine candidate TAK-003 demonstrated in a global PIII trial protection against virologically-confirmed dengue (VCD), the trial’s primary endpoint. The study called TIDES evaluated over 20,000 subjects in Latin America and Asia,…
To read the full story
Related Article
- Takeda’s Dengue Vaccine Approved in Brazil
March 15, 2023
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…